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Abstract Purpose: Stromal alterations are observed following preoperative systemic therapy in breast
cancer. The aim of the present study was to analyze the qualitative and quantitative changes of
representative tumor stroma proteins in the context of neoadjuvant therapy and the response of
patients undergoing preoperative systemic therapy.
Experimental Design: Fifty women receivingpreoperative systemic therapy were evaluated for
clinical and pathologic parameters. Clinical response was defined according to International
Union against Cancer (UICC) criteria, whereas pathologic responses to preoperative systemic
therapy were defined according to the Chevallier and Sataloff classifications. The expression of
tenascin-C, syndecan-1, collagen IV, and smooth muscle actin proteins was investigated using
morphometric analysis of immunohistochemical reactions. Quantitative reverse transcription-
PCR was done to evaluate the mRNA expression level of syndecan-1and tenascin-C. The data
were comparedwith 20 breast cancer samples of patients not treatedwith preoperative systemic
therapy.
Results: According to UICC criteria, the expression levels of collagen IV were up-regulated in all
preoperative systemic therapy ^ treated patients (P = 0.002). Collagen IVwas up-regulated in the
preoperative systemic therapy group inbothChevallier andSataloff classifications comparedwith
the control cases (P = 0.025 and P = 001, respectively).There were no significant differences in
the expression of smooth muscle actin between the treated and nontreated groups. The synde-
can-1proteoglycan level was significantly down-regulated in the preoperative systemic therapy
group (Chevallier classes P = 0.015, Sataloff classes P = 0.015).Tenascin-C was up-regulated in
womenwith progressive disease (P = 0.005).
Conclusion:Wehave observed that the stromal component of breast carcinomas followingpre-
operative systemic therapy differs from the nontreated tumors, which can be evaluated with the
analysis of the above mentioned proteins.
Over the past 15 to 30 years preoperative systemic therapy has
been used to treat locally advanced and inflammatory breast
carcinomas to make surgical therapy possible and to improve
patient survival. Although long-term follow-up data do not
support increased overall patient survival due to preoperative
systemic therapy (1–6), this strategy has been extended and is
recently being used for the treatment of patients with operable
breast carcinomas to increase the rate of breast conservation.
There are many controversial discussions on the benefits and
risks of preoperative systemic therapy. It is generally accepted
that preoperative systemic therapy results in clinical response in
60% to 90% of patients, whereas pathologic complete
response, the predictor of survival, occurs only in 3% to 16%
of patients (7, 8).
Following preoperative systemic therapy there is a significant
change in the appearance of the tumor tissue; most strikingly
the stromal alterations are visible during standard pathologic
assessment. Once the surgical resection is done in a patient
giving complete pathologic response, thus not giving evidence
of the resection being done at the right location, there is need
for a biological marker that can state the site of the original
tumor in an efficient manner.
Despite the multitude of clinical trials and basic research
concerning preoperative systemic therapy for breast cancer
patients, there are still fundamental unanswered questions
from a biological perspective. Which genetic and epigenetic
factors influence the results of preoperative systemic therapy? Is
there an expression change of stromal matrix proteins after
preoperative systemic therapy or, for example, are distinct
tumors foredoomed to fail to express proteins related to good
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response/behavior? From a pathologic perspective, it is not
clear to what extent the published results depend on the
different classification systems of pathologic complete re-
sponse. From a clinical perspective, it is still a matter of debate
how the response to preoperative systemic therapy should be
predicted.
To date, the classification of tumors being responsive or
nonresponsive to preoperative systemic therapy remains
controversial. The pathologic markers such as estrogen receptor
and progesterone receptor status, human epidermal growth
factor receptor 2/neu, p53, and Ki-67 immunohistochemistry
are not useful in predicting the tumor responsiveness to
preoperative systemic therapy (9, 10). As the response rate of
breast cancers to preoperative systemic therapy is a short-term
marker but with a long-term outcome and severe influence on
patient lives, it is important to identify new and reliable factors
that may predict the response to preoperative systemic therapy.
Up to now, the influence of the microenvironment on tumor
cell survival and on the success of chemotherapy has been the
subject of intense studies. The extracellular matrix is a complex
structure of structural proteins, adhesive proteins, and proteo-
glycans that provide essential factors for tumor development,
detachment of cells, and migration (11). Recent research
studies and publications point out the important role of
extracellular matrix components in the effectiveness of chemo-
therapy as well (12, 13).
The extracellular matrix plays an important role in
modulating breast cancer cell behavior: structural proteins,
e.g., basal membrane proteins (collagen IV), represent a
barrier which preserves the structural integrity of ductal
epithelial cell layers, whereas cell surface proteoglycans (such
as syndecan-1) modulate tumor cell adhesion, proliferation,
and angiogenesis. Collagen IV is the most abundant protein of
basal membranes, thus being very durable against mechanical
and proteolytic insults (14). Collagen IV contributes to the
proliferation of mammary epithelium, and is a major target
for matrix metalloproteinase–mediated disruption of basal
membrane during tumor cell invasion as well (15). The a-
smooth muscle actin can be found in the myoepithelial cells
of the breast ducts and in the smooth muscle cells and
pericytes of vessels. In fibrocytes the up-regulated expression
of smooth muscle actin can be the result of the activation of
transforming growth factor-h (TGF-h) signaling in carcinomas
(16). Syndecan-1 is a transmembrane-anchored heparan
sulfate proteoglycan that can be converted into a soluble
effector via matrix metalloproteinase–mediated shedding
(17). It modulates a multitude of biological processes relevant
to tumor progression, acting as a receptor for interstitial
matrix proteins, and as a coreceptor that facilitates signal
transduction through receptors regulating cell proliferation,
chemokine activity, and protease activities (18). Studies in a
xenograft breast cancer model indicate a modulation of tumor
angiogenesis by stromal syndecan-1 (19), conforming with
clinical correlation studies showing coexpression of syndecan-
1 and markers of angiogenesis (20, 21). Syndecan-1, a
transmembrane heparan sulfate proteoglycan, is in the plasma
membrane and regulates cell behavior through regulatory
proteins. Although early studies provided evidence that
heparan sulfate acts to suppress the malignant phenotype,
evidence is mounting that heparan sulfate can also promote
tumor growth and metastasis. Another adhesion modulatory
extracellular matrix molecule, tenascin-C is a factor in the
tumor-specific microenvironment that is highly expressed in
most solid tumors. Tenascin-C actions promote malignant
transformation, uncontrolled proliferation, metastasis, angio-
genesis, and escape from tumor immunosurveillance (22, 23).
Preliminary results have shown that syndecan-1–expressing
carcinomas show decreased response to chemotherapy (5).
Ilunga et al. (24) described the association of tenascin-C
expression with disease progression and poor prognosis.
Considering the above-mentioned information on the role
of syndecan-1 and tenascin-C, these two extracellular matrix
members are analyzed in our study in detail. The induction of
changes in matrix protein expression as a consequence of
preoperative systemic therapy can have a profound influence
on breast cancer pathobiology, and potentially on clinical
outcome. In the present study we analyzed the qualitative and
quantitative changes of representative tumor stroma proteins
following preoperative systemic therapy in the context of the
response rate of breast cancer patients undergoing neo-
adjuvant therapy, because only very few studies in this area
on preoperative systemic therapy patient collectives are
currently available.
Patients andMethods
Clinical records and surgical samples of patients receiving preoper-
ative systemic therapy were evaluated for clinical and pathologic
parameters. Fifty patients had available preoperative and postoperative
immunhistochemical evaluation among the cases diagnosed in our
institute from 2001 to 2007. The median age of the patients was 54.9 y
(range, 29-73 y). Originally the diagnosis of carcinoma was established
Translational Relevance
Preoperative systemic therapy in operable breast cancer
allows the increase of breast conservation rates and offers
theability todiscerntreatmenteffectivity invivo.TheNation-
al AdjuvantBreast andBowel Project trial establishedpath-
ologic complete response as a prognostic marker. Recent
results showed that stromal enhancement ratio detectedby
dynamiccontrast-enhancedmagnetic resonance imagingis
a potential indicator of response to preoperative systemic
therapyandofoveralloutcomeinpatientswithbreastcancer.
We have identified three stromal components (collagen IV,
tenascin-C, and syndecan-1) that differentially expressed in
tumors of preoperative systemic therapy ^ treated patients
compared with nontreated cases. Recent studies have
shownthatpatientswithbreast cancerhave elevated serum
levelsofcollagenIVcomparedwithhealthywomen,andcol-
lagen IV levels increase further during chemotherapy.There
areencouragingresultsofapilot studyseekingthefeasibility
andassess theefficacyamongmalignantgliomapatients,of
administering 131I-labeled murine anti-tenascinmonoclonal
antibody.Syndecan-1^ expressingbreastcarcinomasshow
decreased response to chemotherapy.We believe that our
data and the results mentioned above indicate that stromal
protein level orquality changesmaybe important biological
andclinicalindicatorsof tumorresponsetopreoperativesys-
temic therapy.
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by fine-needle aspiration (in 38 cases) or core-needle biopsy (24 cases)
and by both methods (in 17 cases) of the primary tumor and/or the
metastasis in the palpable axillary lymph nodes. Distant metastases
were screened and their absence was confirmed by chest X-ray,
abdominal sonography, and bone scan. Patients were treated by
different cycles of anthracyclin-based or taxane-based regimens accord-
ing to the following protocol: All 50 patients had locally advanced
disease (large tumor compared with breast size, or breast carcinoma
with axillary metastasis at the time of the diagnosis). Those patients
with axillary metastasis were treated with taxanes, whereas those
without regional spread of the tumor underwent anthracyclin-based
regimens. The pathologic response to preoperative systemic therapy was
defined by the use of the Chevallier classification (25) and the Sataloff
classification for the primary tumor (26). The clinical response to
preoperative systemic therapy was classified according to the UICC
criteria (27). Supplementary Table S1 presents detailed descriptions of
the classification systems.
The expression levels of the above mentioned proteins were
compared with 20 breast cancer samples of patients not treated with
preoperative systemic therapy. The clinicopathologic parameters of
patient cohorts are presented in Table 1. A general assessment was done
comparing the two cohorts to see whether this latter group—diagnosed
with invasive carcinoma from 2001 to 2003—can be used as a control
population. The control tumors had available immunohistochemical
data and were selected to represent matching tumor-node-metastasis
status to the preoperative systemic therapy–treated patients.
Immunohistochemistry. With the use of immunohistochemistry, the
expression of the following extracellular matrix proteins were analyzed:
structural proteins (collagen IV, smooth muscle actin), a proteoglycan
(syndecan-1), and an adhesion molecule (tenascin-C).
The immunohistochemical reactions were done on 5-Am-thick
paraffin sections. The deparaffinization steps were carried out for all
the slides in the same way: after treatment in xylene (twice for 10 min),
an ethanol gradient (96%, 75%, 50%) was used, each for 5 min
followed by washing in PBS. Different antigen retrieval methods were
used. For collagen IV and smooth muscle actin, antigen unmasking
solution (Vector Laboratories) was used for 6 min. For syndecan-1, the
slides were treated in microwave oven in a pH6.0 antigen retrieval
solution (DAKO North America, Inc.) for 30 min. For tenascin-C,
antigen retrieval was done in two steps: the slides were treated in
antigen retrieval solution first (DAKO) for 30 min, followed by
digestion with pepsin for 6 min. Monoclonal antibodies from DAKO
were applied (Supplementary Table S2). Visualization was done with a
standard three-step streptavidin-peroxydase system using 3,3-diamino-
benzidine as chromogen. The reactions were carried out in a Ventana ES
automatic immunostainer (Ventana Medical Systems, Inc.) using the
reagents provided by the manufacturer. The sections were counter-
stained with hematoxylin. Positive control cases with known reactivity
or tissues recommended by the manufacturer were included in every
run. A negative control with omission of the primary antibody was
included for all of the analyzed proteins.
The immunohistochemical analysis was done in two ways: semi-
quantitatively and by morphometric software. Ten representative digital
photos were taken from each case at magnification of 200 (1,320 
1,024  24 b in pixels) using an Olympus BX50F-3 microscope and
DP70 digital CCD camera (Olympus Co.).
The images of the immunohistochemical reactions were analyzed
with Leica Qwin V3.1.0 morphometric software (Leica Microsystems
Imaging Solutions Ltd.) enabling an objective quantification of the
immunohistochemical results. Binary transformation was done, and
threshold levels were selected on the positive control tissues (collagen
IV, R = 247, G = 188, B = 135; smooth muscle actin, R = 229, G = 182,
B = 145; syndecan-1, R = 180, G = 116, B = 82; tenascin-C, R = 217,
G = 182, B = 169, respectively). Evaluation was done on each
digitalized image after correction for possible errors occurring from
inhomogene tissue samples: rejecting the lumen of vessels and ducts
with manual selection. The units of expression were based on pixels.
Real-time reverse transcription-PCR mRNA detection for syndecan-1
and tenascin-C. The formalin-fixed and paraffin-embedded blocks
previously used for the immunohistochemical analyses were used for
the evaluation. Depending on the size of the dissected area, two to eight
5-Am-thick sections were cut from each tissue block and placed in
1.5 mL RNase-free centrifuge tubes. RNA was extracted using the High
Pure RNA Paraffin kit (Roche) according to the manufacturer’s
protocol. After total RNA isolation, samples were kept at -80jC until
further use. Total RNA integrity was verified as described previously
(28). Five hundred nanograms of total RNA were reverse-transcribed at
37jC for 120 min with High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems-ABI) in the presence of RNase inhibitor (ABI).
The real-time reverse transcription-PCR (qPCR) reaction was done
for syndecan-1, tenascin-C, and reference GAPDH genes using 2 AL
complementary DNA template in a total volume of 25 AL using Power
SYBR Green PCR Master Mix (ABI) and ABI Prism 7000 sequence
detection system followed by melting curve analysis from 55jC to
95jC. The qPCR was done in duplicates in 96-well plates with the
following running conditions: initial denaturation at 95jC for 10 min,
then 40 cycles at 95jC for 15 s, at 60jC for 1 min, and finally at 72jC
for 1 min. No primer-dimer formations were observed during the
40 qPCR amplification cycles. Tenascin mRNA expression was analyzed
with two specially designed primer pairs. Alternative splicing of
fibronectin-like repeats of tenascin-C generates a number of splice
variants. As the material used for this study is paraffin-embedded, only
the small variants (f200 bp) should be reliably detected. Melting
analyses as well as gel electrophoresis were done after PCR reactions.
The primer pairs used were as follows:
Syndecan-1 (GI: 55749479): forward 5¶-GCCGCAAATTGTGGC-
TACT-3¶; reverse 5¶-GCT GCG TGT CCT TCC AAG T-3¶
Tenascin-C (GI: 89161216): forward 5¶-CAATCCAGCGACCAT-
CAACG-3¶; reverse 5¶-CGTCCACAGTTACCATGGAG-3¶
ten 9/14: forward 5¶-GGCATCCACTGCCAAAGAAC-3¶; ten 14/16
reverse 5¶-TTCGGCTTCTGTCGTGGC-3¶
GAPDH (GI: 7669491): forward 5¶-CATTGACCTCAACTACATGG-3¶;
reverse 5¶-GAAGATGGTGATGGGATTTC-3¶
Statistical analysis. We analyzed the correlation between high or
low expression of the four examined proteins and the clinical and
pathologic response by using independent-samples t test between
groups. On the protein level, all individual numerical values of the
distinct measurements of the image analysis were included in the
statistical evaluation, which was done using SPSS 15.0 version. The PCR
data analysis and statistical evaluation were accomplished with the
REST tool6 using pairwise fixed reallocation randomization test (29).
This is a relative expression analysis based on the expression ratio of
a target gene versus a reference gene (GAPDH). Clinical response was
assessed as ‘‘responding’’ (complete or partial response) or ‘‘non-
responding’’ (stable disease or progression). The pathologically
complete response was represented in the groups of class I and II of
the Chevallier classification or T-A and T-B classes of the Sataloff
classification. P values <0.05 were considered to be statistically
significant.
Results
According to the Chevallier classification, 7 patients were
classified as class I, 6 as class II, 18 as class III, and 19 as class
IV. Classes I and II represent the complete pathologic response
group (the group of patients in whom no invasive tumor was
further found in the surgical specimen) with 13 patients.
6 http://www.wzw.tum.de/gene-quantification
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According to the Sataloff classification, there were 7 patients
classified as class A, 11 as class B, 17 as class C, and 15 as class
D. According to the UICC clinical response criteria, 10 patients
had complete response, 7 reached partial response, 22 had
stable disease, and in 11 cases progression was observed.
Table 2 shows the results of the different classification methods.
Among all the 50 preoperative systemic therapy treated cases
there were 17 triple-negative carcinomas, among which 4
tumors were positive for CK5/6 immunostaining as well. These
cases were noted to contribute to 58% of the clinical complete
response group.
Increased collagen IV expression was detected in the
extracellular matrix of the treated tumors compared with the
previously untreated carcinomas. Collagen was noted along
basal membranes of healthy mammary ducts, around in situ
carcinomas, and responding tumor cell nests as well (Supple-
mentary Fig. S1).
Smooth muscle actin was present in myofibroblasts, myoe-
pithelial cells, and in blood vessels (Supplementary Fig. S2). In
11 of 50 cases (22%), high smooth muscle actin expression was
detected in the stromal myofibroblasts.
Moderate to strong syndecan-1 expression was observed at
least focally in stromal fibroblasts in 23 (46%) of the
preoperative systemic therapy cases. Syndecan-1 expression of
the carcinoma cells was variable, ranging from completely
negative to strongly positive (Supplementary Fig. S3). In
contrast to the carcinoma, no or only weak stromal syndecan-
1 staining was detected in normal breast tissue stroma
surrounding breast carcinoma.
Tenascin-C staining was noted periductally and in the stroma
if present (Supplementary Fig. S4). Tenascin-C was not present
either in the stroma or periductally in 5 (10%) tumors
irrespective of the pathologic response. Normal adjacent tissue
surrounding tumors showed weaker staining or no tenascin-C
expression.
The collagen IV, smooth muscle actin, syndecan-1, and
tenascin-C protein expression levels of the Chevallier and
Sataloff pathologic response classification groups were com-
pared with the samples of breast cancer patients who did not
receive preoperative systemic therapy (CC group). Among the
structural proteins, the expression of collagen IV was signifi-
cantly up-regulated in all four groups both in the Chevallier
and Sataloff classifications (P = 0.025 and P < 0.001,
respectively). No significant differences were observed
concerning the smooth muscle actin expression between the
different groups, but there was an up-regulation of smooth
muscle actin in the Chevallier class II group compared with the
control group. The syndecan-1 proteoglycan levels were down-
regulated in all four groups (P = 0.015 and P = 0.015,
respectively) compared with the nontreated group. The
adhesion molecule tenascin-C was significantly up-regulated
in the Chevallier IV class of patients (P = 0.008) and the
according to the Sataloff D class of patients (P = 0.003).
According to the UICC criteria, the expression levels of
collagen IV were up-regulated in all the preoperative systemic
therapy–treated patients (P = 0.002). There were no significant
differences in the expressions of smooth muscle actin and
syndecan-1 between the treated and the nontreated groups.
Tenascin-C was up-regulated in women with progressive
disease (P = 0.005). Figure 1 contains the graphs showing the
results of the morphometric evaluation. Supplementary Table
S3 shows the results of morphometric analysis of the
immunohistochemical reactions according to the classification
systems, respectively.
Next, we analyzed the data according to their possible
prognostic value. The expression of collagen IV was significantly
up-regulated in the responding group versus the nonresponding
group based on all the classification methods (Chevallier,
Sataloff, and UICC at P = 0.022, P = 0.035, and P = 0.029,
respectively; see Fig. 2 for the graphs showing the prog-
Table 1. Clinicopathological parameters of the
evaluated patient groups
n %
Patient group PST Control
Age, y*, mean (range) 54.9 (29-73) 60.3 (43-85)
Histologyc
IDC 43/50 (86) 20/20 (100)
ILC 5/50 (10) 0
Other 2/50 (4) 0
Immunohistochemistryb
Estrogen receptor 20/50 (40) 16/19 (84)
Progesterone receptor 9/50 (18) 5/19 (26)
HER2/neu 21/50 (42) 1/19 (5.26)
CK5/6 4/50 (8) 0
pTc
pT0 6/50 (12) 0
pT1 20/50 (40) 16/20 (80)
pT2 15/50 (30) 1/20 (5)
pT3 4/50 (8) 0
pT4 5/50 (10) 3/20 (15)
Lymph node metastasisc
Not present (pN0) 22/50 (44) 9/20 (45)
Present (pN0 <) 28/50 (56) 11/20 (55)
Histologic gradec
Grade 1 4/44 (9.1) 7/20 (35)
Grade 2 17/44 (38.6) 8/20 (40)
Grade 3 23/44 (52.3) 5/20 (25)
Abbreviations: PST, preoperative systemic therapy; IDC, invasive
ductal carcinoma; ILC, invasive lobular carcinoma; HER2, human
epidermal growth factor receptor 2; CK5, cytokeratin 5.
*Mean (range).
cNumber of cases/ all cases (%) in the PST group ypT is given
histologic grade after surgery, following neoadjuvant therapy in
PST group.
bNumber of positive cases/all cases (%).
Table 2. Results of the evaluation of the
pathological and clinical response to primary
systematic therapy according to the Chevallier
and Sataloff classifications and UICC criteria
Chevallier Sataloff UICC
Class I 7 T-A 7 cCR 10
Class II 6 T-B 11 cPR 7
Class III 18 T-C 17 cSD 22
Class IV 19 T-D 15 cPD 11
Abbreviations: cCR, clinical complete response; cPR, clinical
partial response; cSD, clinical stable disease; cPD, clinical
progressive disease.
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Fig. 1. Box-plot diagrams showing the results of the morphometric evaluation of the analyzed stromal proteins. Collagen IV (1st line), smooth muscle actin (2nd line),
syndecan-1 (3rd line), and tenascin-C (4th line) expression in the preoperative systemic therapy (PST) groups compared with the control (CC) group. Classification:
pathologic Chevallier (1st column) and Sataloff classifications (2nd column), and clinical assessment according to UICC criteria (3rd column).
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nostic groups separately). The expression of tenascin-C was
up-regulated in the progressive patient group (Fig. 3). Taken
either in the pathologic (Chevallier or Sataloff) or the clinical
(UICC) classification method, this protein was detected to be
increased in the progressing carcinomas (P = 0.012, P = 0.004,
and P < 0.001, respectively). Although syndecan-1 expression
was statistically significantly down-regulated in the preoperative
systemic therapy–treated group compared with the nontreated
patients, from the point of view of response the evaluated
groups did not differ from each other significantly.
According to the final qPCR data, syndecan-1 was down-
regulated in the preoperative systemic therapy group compared
with nontreated cases, but there were no statistically significant
differences between the analyzed response classes (Fig. 4).
Tenascin-C was up-regulated in all treated cases, but
statistically significant up-regulation (11.86 fold; P = 0.012)
was observed in the progressive disease group only, in the
Chevallier class IV, and the according Sataloff class D patients
(Fig. 4). PCR data are presented in Supplementary Table S4.
Discussion
Several studies have analyzed the role of biological markers
to predict response to preoperative systemic therapy in breast
carcinomas. At present, no biological markers are useful
enough to predict response to chemotherapy or preoperative
systemic therapy (30). Previous studies have examined the role
of certain biological characteristics and markers of tumors
(involved in proliferation, cell cycle, hormonal pathways) in
predicting the likelihood of response to preoperative systemic
therapy (31–33). However, their exact role in prediction is
uncertain. The aim of our study was to analyze the expression
levels of representative extracellular matrix components follow-
ing preoperative systemic therapy, and to evaluate these
changes in the light of clinical and pathologic response.
The triple-negative breast carcinomas with or without CK5/
6-positive immunostaining contributed to the majority of the
clinical complete response group, similar to the finding of
Leivonen et al. (34). Thus, this patient group may be the
appropriate target for primary chemotherapy. To date the
biological classification of tumors as responsive or nonre-
sponsive to treatment remains controversial. Several mecha-
nisms involved in chemoresistance (multidrug resistance
associated proteins, alteration in pathways that influence
DNA repair, apoptosis or cell cycle) have been extensively
studied (35, 36). Recent results point out the important role of
the extracellular matrix components in the success of
chemotherapy as well (12).
The extracellular matrix can interact with tumor cell integrins
and affect tumor cell sensitivity to chemotherapeutic drugs
(37). Rintoul and Sethi suggested that the tumor cells may
condition the neighboring stroma to synthesize protective
extracellular matrix proteins (38, 39).
In our study we found that the expression of collagen IV was
significantly up-regulated in all four groups according to both
pathologic classification systems. Increased expression of
collagen IV may implicate improved structural integrity of the
breast epithelium. Further, the expression of collagen IV was
found to be even more increased in the responding carcinomas
in this study. Also, degradation or loss of the basement
membrane collagen IV was found to promote tumor metastasis
(40). Thus, an increase in collagen IV expression is very likely to
be of beneficial nature, as seen in the responder group.
There were no significant differences in smooth muscle actin
protein expression in the analyzed groups, which may result
from no differences after chemotherapy affecting the tissues
containing smooth muscle actin (e.g., microvessel density). A
very recent study found no changes in nuclear pleomorphism
Fig. 2. Box-plot diagrams showing the significant up-regulation of collagen IV
in the pathologically (Chevallier I and II; Sataloff A and B) and clinically
responsive (UICC complete response and partial response) groups compared with
the nonresponding carcinomas (Chevallier III and IV; Sataloff C and D, UICC stable
disease and progressive disease).
Cancer Therapy: Clinical
www.aacrjournals.orgClin Cancer Res 2009;15(2) January15, 2009 736
Cancer Research. 
on December 13, 2014. © 2009 American Association forclincancerres.aacrjournals.org Downloaded from 
and hormone receptor status of tumors comparing their state
before and after the chemotherapeutic treatment (41).
Syndecan-1 is an important prognostic marker in breast
cancer, and its biological functions include a coreceptor role for
mitogenic growth factor signaling, a role in modulating tumor
angiogenesis, and modulation of cell adhesion and motility
(42). Syndecan-1–deficient mice are resistant to breast cancer
(43). Here we found that syndecan-1 was decreased in the
preoperative systemic therapy–treated patients compared with
nontreated ones, more likely in nonresponding carcinomas,
but the difference was not significant compared with the
responder group.
Little is known about the role and predictive value of
proteoglycans according to the response to neoadjuvant
chemotherapy. We found decreased syndecan-1 expression in
all treated tumors compared with the control group. Go¨tte et al.
showed that the pathologic response to chemotherapy was
decreased in syndecan-1–positive patients and that no synde-
can-1–positive patient showed complete remission (5). Taking
into consideration the aforementioned results and those
observed by Leivonen et al. that concomitant expression of
syndecan-1 in both tumor cells and stroma may be a predictor
of unfavorable prognosis in breast cancer, whereas the loss of
epithelial syndecan-1 is associated with a more favorable
prognosis (34), it seems that the loss of syndecan-1 expression
might be considered as a predictive factor for response to
preoperative systemic therapy.
It is known that tenascin-C up-regulates the expression of
growth-associated genes (cyclin-1, c-myc) in mammary epithelial
cells and tenascin-C increases endothelial cell migration and
growth factor–dependent endothelial cell sprouting (22, 44).
High tenascin-C expression in breast cancer was shown to have
an adverse effect on survival. Tenascin-C is an extracellular
matrix protein that is expressed at low levels in normal adult
tissue but is highly expressed around poor prognosis breast
carcinomas (44). In this study syndecan-1 was down-regulated
in all four groups as opposed to tenascin-C, which was
significantly up-regulated in the Chevallier IV and the Sataloff
D class of patients. Tsanou et al. have shown a negative
correlation between syndecan-1 protein expression and collagen
IV and tenascin-C in breast cancer, which is similar to our
findings (45). Tenascin-C has also been shown to modulate
integrin, but not endothelin receptor signaling via interactions
with a different member of the syndecan family, syndecan-4 (46,
47). There is still a question if preoperative systemic therapy does
Fig. 3. Box-plot diagrams showing the significant up-regulation of tenascin-C in
the pathologically (Chevallier IV; Sataloff D) and clinically progressive groups
compared with the nonprogressing carcinomas (Chevallier I to III; Sataloff A to C,
UICC complete response, partial response, and stable disease).
Fig. 4. Graph showing the results of the PCR analysis of syndecan-1and tenascin
C expression.The syndecan-1was down-regulated in the treated carcinomas,
whereas tenascin C expression was elevated with resistance (stable disease) and
progression (progressive disease; P = 0.012), correspondingly.
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change distinct cells’ individual properties, or from the aspect of
tenascin-C if it facilitates the contraselection of the more
malignant tumor cell populations not responding to neo-
adjuvant therapy. One could suggest that tenascin-C–expressing
cells may be more resistant to preoperative systemic therapy, or
those cells surviving are capable of changing their expression and
producing more tenascin-C as this molecule is suggested to
contribute to the tenacious attribute against chemotherapy.
In a study by Sethi et al. the elevated expressions of collagen
IV, fibronectin, and tenascin-C have been found in most cases
of small cell lung cancers examined. These proteins were found
to protect small cell lung cancers from chemotherapy-induced
apoptosis (39). In addition, syndecan-1 may be implicated in
the regulation of apoptosis, as a recent report has shown
inhibition of n-3 polyunsaturated fatty acids induced apoptosis
in syndecan-1–silenced breast cancer cells (48).
Studies by Miyamoto et al. suggested that long-term exposure
of cancer patients to antitumor drugs is associated with the up-
regulation of extracellular matrix genes in tumor samples (49).
Understanding how the tumor stroma influences adhesion and
tissue architecture to modulate tumor cells survival should help
to better analyze the events that regulate resistance or response
to preoperative systemic therapy. It seems that tumor cells may
produce their own extracellular matrix molecules and the
corresponding growth factors may influence stromal produc-
tion of extracellular matrix.
Conclusion
The choice of treatment in preoperative systemic therapy is
based on assessments of hormone receptor status, nuclear
grade, human epidermal growth factor receptor 2 status, and
not ultimately on the microvessel density. The composition of
the extracellular matrix and its receptors are not routinely
considered as prognostic or predictive factors. Our results
suggest that stromal changes occur in breast carcinoma during
and/or after preoperative systemic therapy, which may be
helpful in diagnostics, and the changes may also differ
according to the response of the tumor. A study with a large
number of patients could support our findings. Up-regulation
of the basement membrane protein collagen IV is presumed,
and decreased expression of the negative prognostic marker
syndecan-1 in all treated cases suggests a beneficial effect on
tumors during and/or after preoperative systemic therapy. Also,
tenascin-C deserves further investigations because it is found to
be up-regulated in the nonresponding group, and thus may be
a marker for the worse prognosis group in the context of
neoadjuvant therapy. Recent studies emphasize the biological
importance of its gene in the aspect of relapse and development
of metastasis as well (50). Evaluation on a larger patient cohort
is desired to establish or reject a classification system based on
stromal matrix protein expression, and to investigate the
consequences of anthracyclin- or taxane-based regimen affect-
ing the tumor stroma.
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